Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Cash and Equivalents of $7.11 million for fiscal year 2024.
ELITE PHARMACEUTICALS INC /NV/ Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $7.11M | -9.3% |
| 2023 | $7.83M | -8.2% |
| 2022 | $8.54M | +167.3% |
| 2021 | $3.19M | +182.1% |
| 2020 | $1.13M | -50.3% |
| 2019 | $2.28M | -68.3% |
| 2018 | $7.18M | -32.2% |
| 2017 | $10.59M | -8.0% |
| 2016 | $11.51M | +54.2% |
| 2015 | $7.46M | +7.5% |
| 2014 | $6.94M | +1781.1% |
| 2013 | $369.0K | -44.8% |
| 2012 | $668.4K | -63.4% |
| 2011 | $1.83M | +215.8% |
| 2010 | $578.2K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2023 | $5.82M | -67.5% | -32.8% |
| September 30, 2023 | $8.65M | -53.4% | -4.7% |
| June 30, 2023 | $9.08M | -54.1% | +15.9% |
| March 31, 2023 | $7.83M | -8.2% | -56.3% |
| December 31, 2022 | $17.91M | +145.7% | -3.5% |
| September 30, 2022 | $18.56M | +313.2% | -6.2% |
| June 30, 2022 | $19.78M | +316.3% | +131.7% |
| March 31, 2022 | $8.54M | +167.3% | +17.1% |
- ELITE PHARMACEUTICALS INC /NV/ showed a decrease of -9.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2024 period, ELITE PHARMACEUTICALS INC /NV/’s cash and equivalents has grown by 1129.1% (from $578.2 thousand to $7.11 million).
- The most recent figure is from ELITE PHARMACEUTICALS INC /NV/’s fiscal year 2023 report (Form 10-K), filed with the SEC on July 1, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: